Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

507
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
507

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-State Memory in 2D Magnets via Thickness-Engineered Growth.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Multidimensional mechanisms of occupational stress among healthcare workers: a structural equation modeling analysis from the seventh Guangxi health service survey.

Frontiers in psychology·2026
Same author

Spatial equity-oriented accessibility assessment and optimal allocation of older adult care facilities in Beijing's central urban area.

Frontiers in public health·2026
Same author

UAV-based spatial sampling bridges ground measurements and satellite data for multi-scale estimation of sugar beet aboveground biomass.

Plant phenomics (Washington, D.C.)·2026
Same author

Near-Unity PLQY and Strong Broadband Emission From 0D (BYA)<sub>4</sub>InCl<sub>7</sub> Enabling High-CRI Solid-State Lighting.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Corrigendum to: Isoorientin alleviates ovalbumin-stimulated allergic rhinitis in mice by restoring Th1/Th2 balance.

Allergologia et immunopathologia·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K

Mycophenolate mofetil for relapsing-remitting multiple sclerosis.

Yousheng Xiao1, Jianyi Huang, Hongye Luo

  • 1Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Lu, Nanning, Guangxi, China, 530021.

The Cochrane Database of Systematic Reviews
|February 8, 2014
PubMed
Summary
This summary is machine-generated.

Mycophenolate mofetil (MMF) showed insufficient evidence for treating new-onset relapsing-remitting multiple sclerosis (RRMS). A small study found no significant effects, with gastrointestinal upset being the main side effect in MMF-treated patients.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

4.1K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Related Experiment Videos

Last Updated: May 3, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.3K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

4.1K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a significant cause of neurological disability in adults.
  • Mycophenolate mofetil (MMF) is an immunosuppressant used in transplantation and autoimmune conditions, including MS.

Purpose of the Study:

  • To evaluate the efficacy and safety of MMF in preventing disease activity in patients with relapsing-remitting MS (RRMS).

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) with at least 12-month follow-up.
  • Searched multiple databases and contacted authors for additional data.
  • Included trials comparing MMF (monotherapy or combination) against placebo or other treatments.

Main Results:

  • One small RCT (26 participants) assessed MMF versus placebo in interferon β-1a-treated RRMS patients.
  • The study had a high risk of bias and limited follow-up, providing inadequate data on relapse, disability, or MRI lesion changes.
  • Gastrointestinal upset was common in the MMF group, but no serious adverse events or discontinuations occurred.

Conclusions:

  • Evidence from one small, high-risk-of-bias study is insufficient to determine MMF's effectiveness as add-on therapy for interferon β-1a in new-onset RRMS.
  • Further research is needed to establish MMF's role in RRMS management.